Johnson & Johnson Stock Price, News & Analysis

Dean Omar Branham Shirley secured two major verdicts against Johnson & Johnson (NYSE:JNJ) in 2024 over asbestos-contaminated talc-based Baby Powder cases. The firm's victories ranked among ALM's Top 100 Verdicts: a $260 million verdict in Oregon for Kyung Lee, a 49-year-old mother diagnosed with mesothelioma (#29), and a $63 million judgment in South Carolina for Michael Perry, a hospitality professional with terminal mesothelioma (#82). The Oregon case included $60M in compensatory and $200M in punitive damages, while the South Carolina verdict comprised $32.6M compensatory and $30.7M punitive damages. Both cases found JNJ liable for knowingly selling asbestos-contaminated products.

A federal jury in Santa Ana, California has unanimously ruled against Johnson & Johnson's (NYSE: JNJ) Biosense Webster unit in favor of Innovative Health, resulting in a $147 million verdict. The jury found that Biosense Webster violated antitrust laws by withholding clinical support from hospitals using Innovative Health's FDA-regulated reprocessed catheters. The Association of Medical Device Reprocessors (AMDR) highlighted this as a victory for hospitals, providers, patients, and the environment. The case exposed anti-competitive practices in medical device reprocessing, where Original Equipment Manufacturers (OEMs) use various tactics to prevent hospitals from using reprocessed single-use devices (SUDs). AMDR provided detailed guidelines for hospitals to combat these practices, including documentation of threats, protection against unauthorized software updates, and rejection of contract clauses restricting reprocessing.

Nachawati Law Group has filed three new lawsuits against Johnson & Johnson (NYSE: JNJ) on behalf of women who developed cancer from using talc-based products, following the dismissal of J&J's third bankruptcy attempt. The legal action resumes after years of delays caused by J&J's "Texas Two-Step" legal maneuvers. Over 50,000 women have alleged developing ovarian cancer from using Johnson's Baby Powder. U.S. Bankruptcy Judge Christopher Lopez rejected J&J's proposed settlement, citing issues with the claimants' voting process and improper attempts to shield non-debtor entities from future liability. The law firm represents thousands of women nationwide and plans to file more cases across different states to hold J&J accountable for what they claim are decades of corporate malfeasance.

Johnson & Johnson (NYSE: JNJ) has announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference scheduled for June 11th, 2025. The company's management will engage in a Fireside Chat session at 3:20 p.m. Eastern Time.

Investors and interested parties can access the live audio webcast through Johnson & Johnson's website at www.investor.jnj.com. A replay of the webcast will be made available approximately 48 hours after the event.

Johnson & Johnson (NYSE: JNJ) announced promising Phase 3 ICONIC-TOTALa trial results for icotrokinra (JNJ-2113), their first-in-class investigational targeted oral peptide for plaque psoriasis. The drug showed significant efficacy in treating high-impact skin sites, with 57% of patients achieving clear or almost clear skin compared to 6% on placebo at Week 16. Notably, 66% of scalp psoriasis patients and 77% of genital psoriasis patients achieved site-specific clearance. The drug demonstrated particularly strong results in difficult-to-treat areas, with 42% of hand/foot psoriasis patients showing improvement. Importantly, icotrokinra maintained a favorable safety profile, with similar adverse event rates between treatment (50%) and placebo (42%) groups, and low serious adverse event rates (0.5% vs 1.9%).

Johnson & Johnson (JNJ) has announced the expansion of its nursing workforce support through J&J CareCommunity, a new social impact platform. This initiative aims to address an expected global nursing shortfall of 4.5 million by 2030. Key programs include: - J&J Nurse Innovation Fellows program with UPenn Nursing and Wharton - Partnership with Aga Khan University training over 3,500 nurses in East Africa - Operation Smile's initiative training 2,880 nurses across 24 countries - WCEA collaboration providing 70 million training hours to nurses in 60+ countries - NurseHack4Health program engaging 5,500+ nurses globally - CofenPlay platform supporting 1+ million nurses in Brazil This expansion builds on J&J's 125+ year history of supporting nurses, including their $50 million Campaign for Nursing's Future which helped add one million nurses to the U.S. workforce.

Johnson & Johnson (NYSE: JNJ) announced promising Phase 3 ASTRO study results for TREMFYA® (guselkumab) subcutaneous (SC) induction therapy in ulcerative colitis (UC). At Week 24, TREMFYA® demonstrated significant improvements across all clinical and endoscopic measures. The drug achieved clinical remission rates of 35.3% (100mg q8w) and 36.4% (200mg q4w) compared to 9.4% for placebo. Endoscopic improvement was observed in 40.3% (100mg q8w) and 45.0% (200mg q4w) of patients versus 12.2% for placebo. TREMFYA® is positioned to become the first and only IL-23 inhibitor offering both SC and IV induction options for UC treatment. The drug showed efficacy in both biologic/JAK inhibitor-naïve and refractory patients, with a safety profile consistent with previous findings. A supplemental Biologics License Application (sBLA) was submitted to the FDA in November 2024 for SC induction approval in UC.

Johnson & Johnson (NYSE: JNJ) announced promising long-term data for TREMFYA® (guselkumab) from the Phase 3 QUASAR study in treating ulcerative colitis (UC). At Week 92, 72% of patients achieved clinical remission, with 99% remaining corticosteroid-free for 8+ weeks. Additionally, 43% of patients reached endoscopic remission, and 84% of patients maintained endoscopic improvement from Week 44 through Week 92. TREMFYA®, the first dual-acting monoclonal antibody blocking IL-23 while binding to CD64, demonstrated sustained efficacy regardless of prior treatment history. The drug received FDA approval for UC treatment in September 2024 and Crohn's disease in March 2025. Safety data remained consistent with TREMFYA's® established profile, with no new concerns identified.

Johnson & Johnson has received FDA approval for IMAAVY™ (nipocalimab-aahu), a groundbreaking FcRn blocker for treating generalized myasthenia gravis (gMG). The treatment is approved for both adult and pediatric patients aged 12 and older who are anti-AChR or anti-MuSK antibody positive, covering over 90% of antibody-positive gMG patients.

Key highlights from clinical trials:

• Demonstrated 20 months of lasting disease control and symptom relief
• Reduced harmful IgG autoantibody levels by up to 75% from first dose
• Showed superior disease control over 24 weeks compared to placebo
• Maintained consistent safety profile in both adult and pediatric populations

Through the IMAAVY withMe program, commercially insured U.S. patients may receive their first treatment within one week and could pay as little as $0 per infusion. The approval follows FDA Priority Review designation and represents a significant advancement in gMG treatment options.